Assessing potential risks of treatment with long-term azithromycin in COPD patients: long-term oxygen users beware?

Irish Journal of Medical Science

Volumn 185, Issue 4, 2016, Pages 993-997

  Nicholson, T T ^a   Franciosi, A ^a   Landers, S ^a   Butler, M W ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Azithromycin maintenance; Chronic obstructive pulmonary disease; Complications; Hearing loss; Screening

Indexed keywords

AZITHROMYCIN; OXYGEN; ANTIINFECTIVE AGENT;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; DRUG USE; ELECTROCARDIOGRAM; FEMALE; FORCED EXPIRATORY VOLUME; HEARING IMPAIRMENT; HEARING TEST; HOSPITAL PATIENT; HUMAN; LONG TERM CARE; MALE; NEUROPSYCHOLOGICAL TEST; OUTPATIENT; OXYGEN THERAPY; POINT OF CARE TESTING; QT PROLONGATION; QTC INTERVAL; RISK ASSESSMENT; RISK FACTOR; WHISPERED VOICE TEST; CHEMICALLY INDUCED; COMPLICATION; CONTRAINDICATIONS; HEARING DISORDER; HEART FAILURE; LONG QT SYNDROME; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; FEMALE; HEARING DISORDERS; HEART FAILURE; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; OXYGEN; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84945297516     PISSN: 00211265     EISSN: 18634362     Source Type: Journal    
DOI: 10.1007/s11845-015-1372-8     Document Type: Article

References (19)

1. Hon AJ, Bach JR (2010) Chronic respiratory care for neuromuscular diseases in adults. Eur Respir J 35(5):1192. doi:10.1183/09031936.00200709 (author reply-3; Epub 2010/05/04)
2. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JAD, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, Make B, Marchetti N, Martinez FJ, Madinger NE, McEvoy C, Niewoehner DE, Porsasz J, Price CS, Reilly J, Scanlon PD, Sciurba FC, Scharf SM, Washko GR, Woodruff PG, Anthonisen NR (2011) Azithromycin for prevention of exacerbations of COPD. N Engl J Med 365(8):689–698
3. Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van’t Veer NE, Ermens AA, Pelle AJ, Hoogsteden HC, Aerts JG, van der Eerden MM (2014) Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2(5):361–368. doi:10.1016/s2213-2600(14)70019-0 [Epub 2014/04/22]
4. Simoens S, Laekeman G, Decramer M (2013) Preventing COPD exacerbations with macrolides: a review and budget impact analysis. Respir Med 107(5):637–648. doi:10.1016/j.rmed.2012.12.019 [Epub 2013/01/29]
5. Albert RK, Connett J, Criner GL, Han M (2014) Azithromycin: we’re there! Am J Respir Crit Care Med 190(9):1074–1075. doi:10.1164/rccm.201408-1436LE [Epub 2014/11/02]
6. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J (2002) Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 57(3):212–216 [Epub 2002/02/28]
7. Haworth CS, Bilton D, Elborn JS (2014) Long-term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questions. Respir Med 108(10):1397–1408. doi:10.1016/j.rmed.2014.09.005 [Epub 2014/10/11]
8. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM (2012) Azithromycin and the risk of cardiovascular death. N Engl J Med 366(20):1881–1890
9. Svanstrom H, Pasternak B, Hviid A (2013) Use of azithromycin and death from cardiovascular causes. N Engl J Med 368(18):1704–1712
10. Albert RK, Schuller JL (2014) Macrolide antibiotics and the risk of cardiac arrhythmias. Am J Respir Crit Care Med 189(10):1173–1180. doi:10.1164/rccm.201402-0385CI [Epub 2014/04/09]
11. Restrepo MI, Anzueto A (2014) Macrolide antibiotics for prevention of chronic obstructive pulmonary disease exacerbations: are we there yet? Am J Respir Crit Care Med 190(1):1–2. doi:10.1164/rccm.201406-1014ED [Epub 2014/07/02]
12. Serisier DJ (2013) Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med 1(3):262–274. doi:10.1016/s2213-2600(13)70038-70039 [Epub 2014/01/17]
13. Bagai A, Thavendiranathan P, Detsky AS (2006) Does this patient have hearing impairment? JAMA 295(4):416–428
14. Pirozzo S, Papinczak T, Glasziou P (2003) Whispered voice test for screening for hearing impairment in adults and children: systematic review. BMJ 327(7421):967
15. Yap YG, Camm AJ (2003) Drug induced QT prolongation and torsades de pointes. Heart 89(11):1363–1372 (PubMed PMID: PMC1767957)
16. Justo D, Zeltser D (2006) Torsades de pointes induced by antibiotics. Eur J Int Med 17(4):254–259. 10.1016/j.ejim.2005.12.003 [Epub 2006/06/10]
17. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359(15):1543–1554. doi:10.1056/NEJMoa0805800 [Epub 2008/10/07]
18. Wang J, Nie B, Xiong W, Xu Y (2012) Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis. J Clin Pharm Therap 37(2):204–11. doi:10.1111/j.1365-2710.2011.01285.x [Epub 2011/07/12]
19. Kardos P, Wencker M, Glaab T, Vogelmeier C (2007) Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175(2):144–9. 10.1164/rccm.200602-244OC [Epub 2006/10/21]